Suppr超能文献

基于转移淋巴结数量和比例的 III 期结直肠癌新分类建议。

Proposal of a new classification for stage III colorectal cancer based on the number and ratio of metastatic lymph nodes.

机构信息

Department of Zhong-Shan-Men In-patient, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, He-Xi District, Tianjin 300171, China.

出版信息

World J Surg. 2013 May;37(5):1094-102. doi: 10.1007/s00268-013-1940-x.

Abstract

BACKGROUND

The objective of this retrospective study was to determine whether the current staging system for stage III colorectal cancer (CRC) is appropriate and to assess the value of the metastatic lymph node ratio (LNR) in predicting the prognosis of patients with stage III CRC.

METHODS

From 2000 to 2006 inclusively, 245 patients with stage III CRC underwent curative resection. The follow-up was closed in March 2012. Kaplan-Meier survival curves and log-rank tests were used for the survival analysis.

RESULTS

Survival time of patients with T3N1M0 was significantly better than that for patients in other subgroups of stage IIIB and similar to that of patients with stage IIIA disease. The greatest survival difference was found with 0.30 as the LNR cutoff point for patients with current stage III CRC. Survival time of patients with LNR ≤ 0.30 was significantly better than that of those with LNR > 0.30. rN1 included stage III patients with LNR ≤ 0.30, and rN2 included patients with LNR > 0.30. Survival time of patients with T4aN1(rN2)M0 staging was significantly worse than that for patients with T4aN1(rN1)M0 staging and similar to that of patients with stage IIIC CRC.

CONCLUSIONS

We propose an algorithm to incorporate LNR into the current American Joint Committee on Cancer staging system. In it the patients with T3N1M0 are excluded from the current stage IIIB and included in the stage IIIA group. Also, patients with T4aN1(rN2)M0 are excluded from the current stage IIIB group and included in the stage IIIC group.

摘要

背景

本回顾性研究旨在确定现行 III 期结直肠癌(CRC)分期系统是否恰当,并评估转移淋巴结比率(LNR)在预测 III 期 CRC 患者预后中的价值。

方法

2000 年至 2006 年期间,245 例 III 期 CRC 患者接受根治性切除术。随访于 2012 年 3 月截止。采用 Kaplan-Meier 生存曲线和对数秩检验进行生存分析。

结果

T3N1M0 患者的生存时间明显优于 IIIB 期其他亚组,与 IIIA 期患者相似。以 0.30 作为当前 III 期 CRC 的 LNR 截止点,生存差异最大。LNR≤0.30 患者的生存时间明显优于 LNR>0.30 患者。rN1 包括 LNR≤0.30 的 III 期患者,rN2 包括 LNR>0.30 的患者。T4aN1(rN2)M0 分期患者的生存时间明显差于 T4aN1(rN1)M0 分期患者,与 IIIC 期 CRC 患者相似。

结论

我们提出一种将 LNR 纳入现行美国癌症联合委员会分期系统的算法。其中,T3N1M0 患者被排除在现行 IIIB 期之外,归入 IIIA 期组。同样,T4aN1(rN2)M0 期患者被排除在现行 IIIB 期之外,归入 IIIC 期组。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验